Ensartinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and is used to treat adults with locally advanced or metastatic non-small cell lung cancer. Ensartinib is associated with transient elevations in serum aminotransferase levels and bilirubin during therapy and rare instances of drug induced liver injury. It is grouped under the following drug class(es): Kinase inhibitors and Tyrosine Kinase Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ensartinibum and SMA5ZS5B22. Its PubChem CID is 56960363.
Ensartinib
| CAS No | 1370651-20-9 |
|---|---|
| Molecular Formula | C26H27Cl2FN6O3 |
| Molecular Weight | 561.4 g/mol |
| Synonyms | 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(3R,5S)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ensartinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and is used to treat adults with locally advanced or metastatic non-small cell lung cancer.
The listed CAS number is 1370651-20-9.
The listed molecular formula is C26H27Cl2FN6O3.
The listed molecular weight is 561.4 g/mol.
6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(3R,5S)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide.
The source lists ensartinibum and SMA5ZS5B22.